Affiliation:
1. Université Picardie Jules Verne
2. INSERM, CNRS, Université Paris Cité
Abstract
Abstract
Background
Calcium is a ubiquitous messenger that regulates a wide range of cellular functions including proliferation, cell migration and apoptosis. Abnormal expression of proteins involved in Ca2+ signaling has been associated with oncogenesis in many solid tumor models. However, its involvement in the pathophysiology of acute myeloid leukemia is less investigated. In this work, we aimed to identify actors of Ca2+ signaling involved in leukemogenesis.
Methods
From an analysis of TCGA and GTEx databases, we identified STIM2, a key sensor regulating Ca2+ capacitive entry, as highly expressed in AML with monocytic differentiation and negatively correlated with overall survival. This was confirmed on a validation cohort of 407 AML patients, showing an association of a high STIM2 expression with adverse risk group according to ELN17 classification. We then investigated the role of STIM2 in cell proliferation, differentiation and survival by modulating its expression in two leukemic cell lines with monocytic potential and in normal hematopoietic stem cells driven into monocytic differentiation.
Results
STIM2 expression increased at the RNA and protein levels upon monocyte differentiation. Phenotypically, STIM2 knockdown drastically inhibited cell proliferation and induced genomic stress with DNA double-strand breaks, as shown by increased p-H2AXγ, followed by activation of the p53 pathway, decreased expression of cell cycle regulators such as CDK1-cyclin B1 and the CDC25c phosphatase, and a decreased apoptosis threshold with a low antiapoptotic/proapoptotic protein ratio. This phenotype was not observed in two p53-deleted cell lines, HL60 and K562. Using a model of in vitro monocytic differentiation of peripheral blood-derived CD34+ cells, we observed higher STIM2 expression at the RNA level in differentiated cells. The acquisition of monocytic markers was faster after STIM2 forced expression, while STIM2 knockdown impaired CD14 expression and led to p-H2AXγ, p53 induction, apoptosis and cell cycle blockage, in agreement with data observed in leukemic cell lines.
Conclusions
In summary, we report STIM2 as a new actor regulating genomic stability and p53 response in terms of cell cycle and apoptosis of human normal and malignant monocytic cells. Considering the association of high STIM2 expression with an adverse prognosis in AML and the association of STIM2 with AML harboring monocytic/myelomonocytic differentiation.
Publisher
Research Square Platform LLC
Reference84 articles.
1. “Acute Myeloid Leukemia Treatment - NCI,” Jul. 06., 2023. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq (accessed Jul. 17, 2023).
2. Ding L et al. “Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing,” Nature, vol. 481, no. 7382, pp. 506–510, Jan. 2012, 10.1038/nature10738.
3. Genetic and Epigenetic Heterogeneity in Acute Myeloid Leukemia;Li S;Curr Opin Genet Dev
4. Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. “Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach,” Cancer, vol. 127, no. 8, pp. 1186–1207, Apr. 2021, 10.1002/cncr.33477.
5. Calcium signaling and cell cycle: Progression or death;Humeau J;Cell Calcium
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献